Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report
Open Access
- 28 July 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (30) , e34349
Abstract
Rationale: Multiple primary malignant tumors are rare and challenging to diagnose. Diffuse malignant peritoneal mesothelioma (DMPM) originate from the peritoneum, which lacks specific clinical manifestations and is difficult to diagnose, with a short survival about 10 to 13 months for inoperable ones. This is the first report of metachronous double primary malignant tumors in nasopharyngeal carcinoma and DMPM accompanied with paraneoplastic syndromes. Patient concerns: A 61-year-old man presented with abdominal discomfort with a history of nasopharyngeal carcinoma 5 years ago. Diagnoses: The diagnosis of DMPM was finally confirmed by laparoscopic mesenteric biopsies. Paraneoplastic syndromes including increased platelets were present when diagnosis, followed by increased neutrophils after disease progression. Interventions: Due to intolerable for surgery, he was treated with pemetrexed combined with nivolumab, intraperitoneal infusion of nivolumab, radiotherapy, anlotinib and maintenance treatment of nivolumab. Outcomes: Progression-free survival in first line is 12 months, overall survival is 23 months. Lessons: This indicate that comprehensive treatment including immunotherapy may be helpful for inoperable DMPM patients with nasopharyngeal carcinoma accompanied with paraneoplastic syndromes.Keywords
This publication has 18 references indexed in Scilit:
- Das diffuse maligne peritoneale Mesotheliom (DMPM) – eine seltene DiagnoseZeitschrift für Gastroenterologie, 2020
- Malignant Peritoneal Mesothelioma: Treatment Options and SurvivalAnticancer Research, 2019
- Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor MicroenvironmentCancer Research, 2018
- Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal ChemotherapyAnnals of Surgical Oncology, 2017
- Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody AvelumabJournal of Thoracic Oncology, 2016
- [Multiple primary malignancies].2012
- Paraneoplastic Syndromes: An Approach to Diagnosis and TreatmentMayo Clinic Proceedings, 2010
- Epidemiology of peritoneal mesothelioma: a reviewAnnals of Oncology, 2006
- Granulocyte-colony stimulating factor- and interleukin 6-producing diffuse deciduoid peritoneal mesotheliomaLaboratory Investigation, 2005
- IL-6 switches the differentiation of monocytes from dendritic cells to macrophagesNature Immunology, 2000